• Target：
• uPA

• Fields：
• >>NF-kappa B signaling pathway;>>Complement and coagulation cascades;>>Transcriptional misregulation in cancer;>>Proteoglycans in cancer;>>MicroRNAs in cancer;>>Prostate cancer

• Gene Name：
• PLAU

• Protein Name：
• Urokinase-type plasminogen activator

• Human Gene Id：
• 5328

• Human Swiss Prot No：
• P00749

• Mouse Swiss Prot No：
• P06869

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human uPA. AA range:190-239

• Specificity：
• uPA Polyclonal Antibody detects endogenous levels of uPA protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• IHC 1:100 - 1:300. ELISA: 1:40000.. IF 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• PLAU;Urokinase-type plasminogen activator;U-plasminogen activator;uPA

• Molecular Weight(Da)：
• 49kD

• Background：
• This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016],

• Function：
• catalytic activity:Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.,function:Specifically cleave the zymogen plasminogen to form the active enzyme plasmin.,online information:Urokinase entry,pharmaceutical:Available under the name Abbokinase (Abbott). Used in Pulmonary Embolism (PE) to initiates fibrinolysis. Clinically used for therapy of thrombolytic disorders.,PTM:Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.,similarity:Belongs to the peptidase S1 family.,similarity:Contains 1 EGF-like domain.,similarity:Contains 1 kringle domain.,similarity:Contains 1 peptidase S1 domain.,subunit:Found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A which is cleaved to yield a short chain A. Binds LRP1B; binding is followed by interna

• Subcellular Location：
• Secreted .

• Expression：
• Expressed in the prostate gland and prostate cancers.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs